Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly … – Markets Insider
Drug Discovery & Development |
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR–T Therapy Predominantly …
Markets Insider This preclinical study demonstrated that Poseida's advanced CAR–T cell therapy could completely eliminate solid tumors in a previously incurable preclinical model of prostate cancer, and was selected for oral presentation today at the 24th Prostate … Endocyte Pursuing Phase 3 Trial of 177Lu-PSMA-617 in Metastatic PC |
